AHA on July 21 submitted comments on how Congress can ensure that the 340B program continues to benefit patients and communities, while acting to prevent any cuts to the program that would jeopardize patient access to care. Responding to a bipartisan request by senators for input, AHA strongly urged that the Health Resources and Services Administration finalize its Administrative Dispute Resolution rule for the 340B program and explicitly state that the ADR process is an available forum for affected 340B hospitals to seek redress from restrictions targeted to community and specialty pharmacies. AHA also recommended that Congress require HRSA to increase its annual audits of drug companies in the 340B program, which average six per year compared with over 200 per year for 340B covered entities, and give hospitals and other covered entities the ability to audit drug manufacturers.

Related News Articles

Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…